WuXi AppTec's CRDMO Model Integrates Research, Development, and Manufacturing

Got story updates? Submit your updates here. ›

WuXi AppTec, a global contract research, development, and manufacturing organization (CRDMO), has introduced an integrated drug development model that combines research, development, and manufacturing into a single end-to-end platform. Unlike traditional fragmented service models, WuXi's CRDMO approach supports the full lifecycle of a drug, from early discovery through preclinical, clinical testing, and commercial manufacturing, within one continuous system.

Why it matters

The CRDMO model addresses key challenges in the life sciences industry, including long development timelines, high costs, and low R&D success rates. By eliminating fragmentation across vendors, the integrated platform enables faster progression from discovery to clinical and commercial stages, reduced operational complexity, and better alignment of development and manufacturing strategies.

The details

At the core of WuXi AppTec's CRDMO model is the integration of research, development, and manufacturing into a unified platform. Unlike traditional CRO, CDMO, and CMO models that operate independently, the CRDMO approach allows for seamless collaboration across scientific disciplines and operational functions. This enables continuous progression from discovery to manufacturing without disruption, with early insights from research informing downstream development and CMC planning.

• WuXi AppTec introduced the CRDMO model in 2026.